You are not logged in.
This means
you CAN ONLY VIEW reports that were published prior to Monday, February 19, 2024.
You
MUST UPGRADE YOUR MEMBERSHIP if you want to see any current reports.
 MIDDAY BREAKOUTS REPORT - FRIDAY, FEBRUARY 21ST, 2014
Previous Mid Day Report Next Mid Day Report >>>
|
|
DOW 16167.91 34.68 (0.21%) | NASDAQ 4281.05 13.5 (0.32%) | S&P 500 1844.43 4.65 (0.25%)
|
Time of Screening :
2/21/2014 12:06:33 PM Report Released :
2/21/2014 12:41:54 PM
Price is:
Above 52W High and Less Than 52W High
but within 10% of the 52 Week High
Volume Is:
At least 75% of 50 Day Average at
the time of the screening.
More details about this report...
At around
mid-way through each trading day we run
a screen against our database of
high-ranked stocks, searching for
possible buy candidates that are trading
at or near their 52-week high on above
average volume. The results of that
screen are split into the two sections
you see below. The first, titled
"TODAY's FEATURED STOCKS" shows stocks
that our experts have recently
identified as among the strongest candidates to
consider. Stocks highlighted in yellow
are the most timely and noteworthy, so
particular attention and prompt action
may be appropriate. The second section,
titled "TODAY's BREAKOUT SCREEN" shows
the remainder of stocks meeting today's
screen parameters. Our experts have
reviewed and included notes on these
stocks as well, but found that they may
not match up as favorably.
|
|
Y - Today's strongest
candidates
highlighted
by our staff
of experts.
|
|
G - Previously featured in
this report as yellow and
now may no longer be buyable
under the guidelines.
|
|
|
Symbol/Exchange
Company Name
Industry Group |
PRICE |
CHANGE
(%Change) |
Day High |
Volume
(% DAV)
(50 DAV) |
52 Wk Hi
% From Hi |
Date
Featured |
Price
Featured |
Pivot Point |
|
Max Buy |
EQM
- NYSE
E Q T Midstream Partners
|
$64.51
|
+0.00
0.00%
|
$65.24
|
89,051
75.47% of 50 DAV
50 DAV is 118,000
|
$67.80
-4.85%
|
12/12/2013 |
$53.17
|
PP = $56.51
MB = $59.34 |
Most Recent Note - 2/21/2014 12:25:22 PM
G - Enduring distributional pressure after recently reporting earnings -2% on +22% sales revenues for the Dec '13 quarter, below the +25% minimum earnings guideline (C criteria), raising fundamental concerns. Its 50 DMA line defines near-term support.
>>> The latest Featured Stock Update with an annotated graph appeared on 2/7/2014. Click here.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
PCLN
- NASDAQ
Priceline.com Inc
|
$1,327.54
|
+44.54
3.47%
|
$1,333.12
|
1,136,291
164.44% of 50 DAV
50 DAV is 691,000
|
$1,313.82
1.04%
|
12/18/2013 |
$1,156.20
|
PP = $1,198.85
MB = $1,258.79 |
Most Recent Note - 2/21/2014 12:39:04 PM
G - Gapped up today hitting another new 52-week high, adding to an impressive streak of gains marked by above average volume. Rallying with no resistance due to overhead supply, getting more extended from any sound base.
>>> The latest Featured Stock Update with an annotated graph appeared on 2/13/2014. Click here.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
|
 |
Symbol - Exchange - Industry Group
Company Name |
Last |
Chg |
Day
High |
52 WK Hi |
% From Hi |
Volume
% DAV |
DAV |
ATK
- NYSE - AEROSPACE/DEFENSE - Aerospace/Defense Products & Services
Alliant Techsystems Inc
|
$133.13 |
+2.86
2.20%
|
$134.08
|
$145.16
|
-8.29% |
307,434
76.86%
|
400,000
|
Most Recent Note for ATK - 2/21/2014 12:07:36 PM
Consolidating -8.4% off its 52-week high. Reported +56% earnings on +14% sales revenues for the Dec '13 quarter and gave encouraging FY '14 guidance recently, but fundamental concerns remain. Found support above prior highs in the $123 area while consolidating since noted with caution in the 1/15/14 mid-day report - "Lack of sales revenues growth is a concern. Quarterly and annual earnings history (C and A criteria) are not a match with the fact-based investment system's guidelines."
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
BIIB
- NASDAQ - DRUGS - Biotechnology
Biogen Idec Inc
|
$348.66 |
+13.55
4.04%
|
$349.77
|
$335.99
|
3.77% |
1,045,466
77.10%
|
1,356,000
|
Most Recent Note for BIIB - 2/21/2014 12:12:37 PM
Hitting new 52-week and all-time highs again with today's gain, extended from any sound base. Found support above its 50 DMA line during its consolidation after a "breakaway gap" when noted with caution on 11/25/13 mid-day report. Reported earnings +67% on +39% sales revenues for the Dec '13 quarter. The prior quarterly comparison showed earnings just below the +25% minimum earnings guideline (C criteria). Sales revenues increases have shown encouraging acceleration. Its annual earnings (A criteria) history has been good. It is already owned by 1,796 top-rated mutual funds.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
CAR
- NASDAQ - Leisure-Services
Avis Budget Group Inc
|
$43.98 |
+0.37
0.85%
|
$44.78
|
$44.64
|
-1.48% |
1,814,157
98.92%
|
1,834,000
|
Most Recent Note for CAR - 2/21/2014 12:16:58 PM
Hitting new 52-week highs with today's 5th consecutive gain. Quarterly and annual earnings history has been erratic and not a match with the fundamental guidelines (C and A criteria) of the fact-based investment system.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
CNOB
- NASDAQ - Banks-Northeast
ConnectOne Bancorp Inc
|
$44.47 |
+0.29
0.66%
|
$44.59
|
$49.25
|
-9.71% |
7,537
75.37%
|
10,000
|
Most Recent Note for CNOB - 2/21/2014 12:18:32 PM
Earnings history is not a match with the fact-based investment system's guidelines.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
CSGP
- NASDAQ - COMPUTER SOFTWARE & SERVICES - Business Software & Services
Costar Group Inc
|
$194.45 |
+11.45
6.26%
|
$195.52
|
$188.43
|
3.19% |
171,140
121.38%
|
141,000
|
Most Recent Note for CSGP - 2/21/2014 12:20:10 PM
Hitting a new 52-week high with today's considerable volume-driven gain, rallying with no resistance due to overhead supply. Reported earnings +70% on +16% sales revenues for the Dec '13 quarter, its 6th consecutive quarter with earnings above the +25% minimum guideline (C criteria). Its annual earnings (A criteria) history included a downturn in FY '10, a flaw with respect to the fact-based investment system's guidelines.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
DATA
- NYSE - HEALTH SERVICES - Medical Laboratories & Researc
Tableau Software Cl A
|
$99.42 |
+2.29
2.35%
|
$100.00
|
$98.61
|
0.82% |
783,030
110.75%
|
707,000
|
Most Recent Note for DATA - 2/21/2014 12:20:53 PM
Hitting another new 52-week high today. Stubbornly held its ground following a considerable 2/05/14 gap up. Prior mid-day reports repeatedly cautioned members - "Reported strong sales revenues and earnings increases for the Sep and Dec '13 quarters but fundamental concerns remain."
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
DTV
- NASDAQ - TELECOMMUNICATIONS - Communication Equipment
Directv
|
$75.53 |
+0.45
0.60%
|
$75.73
|
$75.50
|
0.04% |
4,653,014
119.43%
|
3,896,000
|
Most Recent Note for DTV - 2/21/2014 12:22:48 PM
Hitting a new 52-week high today. Reported -1% earnings on +7% sales revenues, below the +25% minimum earnings guideline (C criteria). Its annual earnings (A criteria) growth has been steady.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
HOLI
- NASDAQ - MANUFACTURING - Industrial Electrical Equipmen
Hollysys Automation Tech
|
$19.70 |
+0.35
1.81%
|
$19.84
|
$19.88
|
-0.91% |
315,984
99.68%
|
317,000
|
Most Recent Note for HOLI - 2/21/2014 12:27:43 PM
Perched at its 52-week high with today's 5th consecutive gain. No resistance remains due to overhead supply. The China-based firm reported earnings +88% on +76% sales revenues for the Dec '13 quarter, its 3rd quarterly comparison with earnings at or above the +25% minimum earnings (C criteria) guideline for buy candidates. Flaws in its annual earnings (A criteria) history previously were noted as a fundamental concern.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
JNPR
- NYSE - COMPUTER HARDWARE - Networking & Communication Dev
Juniper Networks Inc
|
$27.73 |
+0.32
1.15%
|
$28.14
|
$28.75
|
-3.57% |
9,348,765
95.24%
|
9,816,000
|
Most Recent Note for JNPR - 2/21/2014 12:29:53 PM
Hovering near its 52-week high, stubbornly holding its ground following a "breakaway gap" on 1/10/14. Reported earnings +54% on +12% sales revenues for the Dec '13 quarter, its 4th consecutive earnings increase above the +25% minimum guideline (C criteria). Prior quarterly sales revenues increases were in the +3-7% range, not indicating truly great demand for any new products or services (N criteria). Its large supply of 505 Million shares (S criteria) outstanding makes it an unlikely sprinter. Up and down annual earnings history is a flaw (A criteria).
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
MFSF
- NASDAQ - BANKING - Savings & Loans
Mutualfirst Financial
|
$19.08 |
-0.07
-0.37%
|
$19.22
|
$20.99
|
-9.10% |
8,358
119.40%
|
7,000
|
Most Recent Note for MFSF - 2/21/2014 12:31:01 PM
The 2/11/14 mid-day report cautioned members - "Reported +35% earnings on -11% sales revenues for the Dec '13 quarter and fundamental concerns remain with respect to the C and A criteria. Low-priced stocks are discouraged from consideration unless all key criteria are solidly satisfied."
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
MYGN
- NASDAQ - DRUGS - Diagnostic Substances
Myriad Genetics
|
$37.59 |
+1.30
3.58%
|
$39.15
|
$38.27
|
-1.78% |
3,723,886
154.90%
|
2,404,000
|
Most Recent Note for MYGN - 2/21/2014 12:34:47 PM
Reported earnings increases above the +25% minimum guideline in past 5 quarterly comparisons through Dec '13, but fundamental concerns remain. Annual earnings history has not been strong and steady, falling short of the guidelines for the A criteria. Powering to a new 52-week high with today's considerable volume-driven gain.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
NVO
- NYSE - DRUGS - Drug Manufacturers - Other
Novo Nordisk A/S Adr
|
$44.98 |
+0.56
1.26%
|
$45.04
|
$44.57
|
0.92% |
2,358,693
144.53%
|
1,632,000
|
Most Recent Note for NVO - 2/21/2014 12:36:24 PM
Perched at its all-time high today tallying another volume-driven gain, on track for its 5th consecutive weekly gain. Reported earnings +14% on +8% sales revenues for the Dec '13 quarter, a 2nd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 232 in Mar '13 to 200 in Dec '13, not a good sign concerning the I criteria.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
UA
- NYSE - CONSUMER NON-DURABLES - Textile - Apparel Clothing
Under Armour Inc Cl A
|
$111.51 |
+4.32
4.03%
|
$112.98
|
$110.00
|
1.38% |
1,289,378
95.86%
|
1,345,000
|
Most Recent Note for UA - 2/21/2014 12:40:35 PM
Hitting another new 52-week high today. Did not form a base of sufficient length yet stubbornly held its ground after considerable volume-driven gains. Prior mid-day reports repeatedly noted - "No resistance remains due to overhead supply as it gapped up today for a considerable volume-driven gain and new all-time highs. Reported strong Dec '13 earnings and encouraging guidance for FY '14. Found support near its 50 DMA line during consolidations in recent months. Since a downturn in the Mar '13 quarter its recent quarterly comparisons have shown earnings increases above the +25% minimum guideline (C criteria) and it has a strong annual earnings (A criteria) history. Patient investors may watch for a new base or secondary buy point to develop and be noted in the weeks ahead."
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
ZBRA
- NASDAQ - COMPUTER HARDWARE - Computer Peripherals
Zebra Tech Corp Cl A
|
$66.47 |
+1.04
1.59%
|
$67.04
|
$65.92
|
0.83% |
205,825
89.49%
|
230,000
|
Most Recent Note for ZBRA - 2/21/2014 12:41:14 PM
Hitting new 52-week highs with an impressive streak of 8 consecutive gains marked by ever-increasing volume including a big "breakaway gap" on the prior session. Found support near its 50 DMA line during its recent consolidation. Reported earnings +28% on +12% sales revenues for the Dec '13 quarter, but prior quarterly comparisons showed sales revenues and earnings increases below the fact-based system's guidelines.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
|
|
|
THESE ARE NOT BUY RECOMMENDATIONS!
Comments contained in the body of this report are technical
opinions only. The material herein has been obtained
from sources believed to be reliable and accurate, however,
its accuracy and completeness cannot be guaranteed.
We are not an investment advisor, hence it does
not endorse or recommend any securities or other investments.
Any recommendation contained in this report may not
be suitable for all investors and it is not to be deemed
an offer or solicitation on our part with respect to
the purchase or sale of any securities. All trademarks,
service marks and trade names appearing in this report
are the property of their respective owners, and are
likewise used for identification purposes only.
This report is a service available
only to active Paid Premium Members.
You may opt-out of receiving report notifications
at any time. Questions or comments may be submitted
by writing to FactBasedInvesting.com c/o Premium
Member Services 665 S.E. 10 Street, Suite 201
Deerfield Beach, FL 33441-5634 or by calling 954-785-1121.
We appreciate any feedback
members may wish to send via the inquiry form
here.
|
|
|
